Severe bradycardia in a teenager as the initial manifestation for Guillain Barré syndrome: a case report

C. Bonilla¹, M. I. Alvarez-Olmos², C. Uribe³* and J. Fernández-Sarmiento⁴

Abstract

Background: Guillain-Barré syndrome is the most common cause of flaccid paralysis, with multiple known clinical variants. Autonomic dysfunction, although frequently reported in the clinical course, is often overlooked in the pediatric population and is usually not the initial presenting symptom in this age group.

Case presentation: We present the case of a previously healthy 17-year-old who arrived at the Emergency Department complaining of gastrointestinal symptoms associated with lipothymia. An initial electrocardiogram (ECG) showed sustained sinus bradycardia subsequently associated with arterial hypertension. Structural and inflammatory cardiac pathology were ruled out, as well as auriculoventricular conduction block and posterior reversible encephalopathy syndrome. On the ninth day after initial symptoms, the patient presented sensory and motor nerve disturbances with the cerebrospinal fluid analysis showing a clear albumin-cytologic dissociation, consistent with an atypical presentation of GBS with autonomic dysfunction. Immunoglobulin therapy was administered, developing subsequent aseptic meningitis, that required discontinuation of previous therapy and treatment with plasmapheresis. Clinical improvement was achieved with full motor function recovery.

Conclusion: This case illustrates a Guillain-Barré syndrome variant in which autonomic dysfunction preceded neurologic deficit, a finding uncommon in children, emphasizing this as an important differential diagnosis for severe bradycardia in pediatric patients.

Keywords: Flaccid paralysis, Variant, Autonomic dysfunction, Pediatric, Plasmapheresis

Background

Autonomic dysfunction, which can occur in 2/3 cases of Guillain-Barré syndrome as an acute presentation before the development of sensory or motor symptoms, has been associated with worse outcomes [1]. Although this presentation is infrequent and difficult to diagnose, this phenotypic variant, with restricted autonomic manifestations, constitutes an acute inflammatory neuropathic event caused by immune-mediated mechanisms that may be successfully treated with plasmapheresis or intravenous immunoglobulin [1, 2].

Case presentation

A previously healthy, 17-year-old male adolescent arrived at the Emergency Room Department on mid-February 2020 complaining of acute-onset of left flank abdominal pain, intensity 5/10, associated with diarrhea and lipothymia. Initial evaluation revealed a heart rate of 20-27 beats per minute (Figs. 1 and 2), requiring immediate transfer to the Pediatric Cardiovascular Intensive Care Unit for further evaluation and monitoring.

Due to the abdominal pain and diarrhea, an infectious etiology was considered and, following blood, urine

*Correspondence: c.uribe10@uniandes.edu.co
³ Medical doctor Universidad de los Andes, Pediatric resident Fundación Santa Fe de Bogotá University Hospital, Bogotá, Colombia
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
and stool cultures, treatment with ceftriaxone was initiated. Laboratory evaluation revealed complete cell blood count, glucose, venous gases, renal function, hepatic function, and serum electrolytes (sodium 139 mEq/L, chloride 110 mEq/L, potassium 4.1mEq/L, calcium 8.9 mg/dL, phosphorus 5 mg/dL, magnesium 1.9 mg/dL) all within normal limits; toxicology screen was negative. Contrasted abdominal CT showed mild concentric wall thickening of descending and sigmoid colon, and inflammatory periportal and perivascular reaction in the soft tissue. Mild leukopenia was observed (WBC count of 4860/mm³), with normal erythrocyte and platelet counts, and a negative C reactive protein (0.01 mg/dL). Early improvement of acute gastroenteritis was observed, and antibiotic treatment was discontinued soon after blood and stool cultures results were negative.

Structural cardiac pathology was ruled out by a normal transthoracic echocardiogram. Holter monitoring showed sinus bradycardia without bundle branch block or other conduction abnormalities, suggesting possible autonomic dysfunction without pacemaker indication (Fig. 1). Cardiac enzymes (troponin, CPK, CPK-MB) ruled out an acute inflammatory process, and alfa-1-adrenergic treatment with Midodrine 2.5 mg every 8 hours with the objective of generating venous vasoconstriction was initiated.

Three days following his admission, he became hypertensive, with systolic arterial pressure readings above 170 mmHg and diastolic levels of 104 mmHg. Renal Doppler ultrasound and ophthalmologic evaluation excluded chronic causes of hypertension. Thyroid and renal function tests, aldosterone, renin, and serum/urine catecholamines were normal. Six days after admission to the Intensive Care Unit, a neuropediatric consult was ordered to evaluate dysautonomic symptoms without sensory, motor or any other pupillary dysfunction present. Diarrheal stools completely resolved during the first day of admission.

Considering persistent vagal-adrenergic autonomic compromise with autonomic dysfunction, associated with initial presenting symptoms suggestive of infective gastroenteritis, dysautonomia variant of Guillain-Barré syndrome was considered. A cerebrospinal fluid analysis showed leucocytes (0.0/mm³), erythrocytes (0.0/mm³), glucose (52 mg/dL), and proteins (594.2 mg/dL) with clear albumin-cytologic dissociation.

Initial nerve conduction studies with F wave and H reflex evaluation in upper and lower extremities
demonstrated normal motor unit morphology, without signs of acute or chronic denervation; discrete decrease in proximal and distal muscle pattern recruitment in all four limbs was subsequently confirmed, with interference pattern of 90% (non-conclusive for acute denervation injury). A gastrointestinal Multiplex Polymerase Chain Reaction (PCR) testing by Film-Array® ruled out Campylobacter spp., Yersinia spp., enterovirus, and other enteric pathogens. Cerebral magnetic resonance was normal, with no evidence of parietal or occipital lesions consistent with posterior reversible encephalopathy syndrome in the context of dysautonomia and severe hypertension. Simple and contrasted sella turcica and cervical, thoracic, and lumbosacral imaging were all normal.

On the ninth day of admission, progressive weakness was observed and associated with extension to the hips resulting in difficulty walking, one episode of urinary incontinence, patellar areflexia, and strength 2+/5 bilaterally in lower limbs. Neither upper limbs, cranial nerves, deglutition nor respiratory muscles were compromised. Hughes scale 3/6 for Guillain-Barré was confirmed.

Intravenous human immunoglobulin G (IVIG) therapy (400 mg/Kg/day) was ordered for 5 days; however, on the third day of treatment, the patient developed a severe headache requiring management with intravenous paracetamol, pregabalin and oxycodone. A simple cranial CT scan was normal, without evidence of acute hemorrhage or edema. Cerebral MRI showed increased leptomeningeal enhancement, particularly in the posterior fossa, compatible with uncomplicated meningitis. A second lumbar puncture was performed, which reported aseptic cerebrospinal fluid consistent with an acute inflammatory process, with a predominance of lymphocytes, hypoglycorrhachia and increased protein concentration. Aseptic meningitis secondary to immunoglobulin therapy was diagnosed, requiring switching to plasmapheresis for Guillain-Barré, and symptom relief was achieved after five sessions. Prior to discharge, patient was able to get independent march. Four months after discharge, he was able to walk and climb stairs without assistance. Complete clinical recovery was observed after 6 months.
Discussion and conclusions

Previous publications have reported that up to 67% of patients with Guillain-Barré Syndrome (GBS) may present with autonomic dysfunction associated with cardiovascular complications such as bradycardia, auriculoventricular block, sinus arrest, sustained sinus tachycardia, and ventricular arrhythmias [1, 2]. Moreover, blood pressure fluctuations, vasomotor dysfunction and intestinal motility dysregulation has also been reported [2]. Although autonomic dysfunction was first described in 1892 [3], in recent decades the need for early recognition and treatment has been emphasized to improve mortality rates, which can reach 7% [4, 5].

Campylobacter jejuni is one of the most frequently agents capable of triggering GBS and the infections usually precedes axonal GBS disease in up to 33% of patients. Furthermore, this infection can result in major damage in patients with GBS compared with other infections [6].

Our patient developed typical presentation of GBS nine days after the initial symptoms of gastroenteritis with negative stool culture for C. jejuni. Although serology testing may be a potential option for diagnosing this infectious agent, this tool is not available in our center. A multiplex PCR (Film-Array®) was performed in stool to identify an infectious cause of gastroenteritis episode without success. There is not a clear etiologic explanation for his initial enteritis and dysautonomic disfunction. However, the diarrheal episode resolved fast, and constipation rapidly began when the dysautonomia became present. At the time of our patient ER consultation on mid of February 2020, SARS-CoV-2 testing was not available since the epidemic was declared until March 2020 and the first local case was reported 3 weeks after his hospital admission.

GBS patients may develop blood pressure fluctuations, such as arterial hypertension (27% of patients), and transitory hypotension or sustained hypotension (3% of cases). Drastic fluctuations between severe hypertension and hypotension may cause cardiovascular collapse and sudden death [4]. These fluctuations are related with increased afferent sympathetic tone, transitory serum catecholamine levels, baroreceptor dysregulation, preganglionic sympathetic axonal demyelination, and/or postganglionic axonal degeneration, producing altered feedback or inappropriate ectopic electrical discharges [7].

To date, the relationship between autonomic nervous system disfunction (blood pressure fluctuations and vasomotor abnormalities) and the degree of severity in GBS patients is unclear. There is not a currently sensitive marker to predict early identification of arrhythmia in those who will likely develop clinic of GBS [8]. Currently known causes of arrhythmias include [2]: 1) autonomic afferent demyelination from the heart; 2) respiratory failure; 3) Brainstem central vagal control (nuclear lesions); 4) independent risk factors for autonomic cardiac innervation, such as direct interstitial infiltrate, with or without myocardial necrosis.

Pupillary dysfunction can also be observed on physical examination in up to 14% of patients with GBS [1], although diagnosis may improve if automatized pupillometry is routinely performed, offering a more objective, accurate and quantitative evaluation of pupillary function (including size and constriction/dilation velocity) [9].

Paralytic ileus has been described in up to 15% of GBS patients secondary to lack of intrinsic neuronal control and extrinsic gastrointestinal pathways, with compromised parasympathetic and sympathetic autonomic nerve fibers [10]. Gastroparesis, delayed gastric emptying, diarrhea as may have occurred in our patient, and/or fecal incontinence are not uncommon findings. It is unclear whether these findings are all secondary to dysautonomia, immobility, or secondary effects of medication such as opioids. Moreover, altered peptide secretion, decreased mesenteric blood flow and gastrointestinal neural pathways have all been hypothesized to play a role.

Identifying autonomic neuropathy as a dysautonomic variant of GBS in the early stages of disease is of utmost importance. Although many different autonomic tests have been developed (e.g., eyeball pressure test, 24-h heart rate power spectrum, head-up tilt test, hand grip testing, cold pressor test, atropine test, catecholamine testing, microneurographic studies and sudomotor testing), studies related to reproducibility, interobserver variability, and predictive value in patients with GBS are lacking [11].

Additionally, studies evaluating blood and urine neurotransmitter levels as substitute markers for the autonomic function in GBS patients, as opposed to vanilmandelic acid and catecholamines, are limited [12]. Moreover, sensory and motor nervous conduction studies through electromyography are not always accurate in GBS variants, as electrophysiologic abnormalities may be mild or unspecific in early disease stages [13].

GBS as an autoimmune polyradiculoneuropathy shows adequate response to early immunotherapy with plasmapheresis or IVIG, improving autonomic symptoms. Although superiority or non-inferiority trials are inconclusive, IVIG is usually preferred as first-line treatment due to its relative simplicity of administration compared to plasmapheresis, as well as greater availability. Recommended dose of 1 g/Kg/day for 2 days or 400 mg/Kg/day for 5 days of IVIG may suppress the inflammatory response [1, 2, 13]. Additional analysis is required to establish which immunotherapy
modality is useful and if plasmapheresis is in fact better than IVIG in GBS with autonomic dysfunction, consid-
ering possible autonomic dysfunction symptom presenta-
tion versus adverse effects from treatment including hypotension or hypertension due to electrolyte imbal-
ance generated by plasmapheresis. However, patients
with autonomic dysfunction require aggressive treat-
ment, either with plasmapheresis or IVIG. Our patient
required switching treatment modality due to aseptic
meningitis, which can be seen as an infrequent adverse
event of IVIG administration, with excellent clinical
improvement following the use of plasmapheresis.

Mild to severe motor disability in GBS may appear in
30% of patients who develop vagal hyperactivity [2]. Nonetheless, little is known about GBS in pediatric
patients regarding this presentation and its prognosis.

Published literature about autonomic dysfunction and progression to GBS indicates that this may be a
transitory phenomenon, with resolution in months [1, 2]. Although an increase in mortality has been reported
in patients with autonomic dysfunction [1], prospective and multicentric studies looking at the relation between
autonomic dysfunction presentation and mortality risk are lacking.

This case illustrates the presence of a GBS variant
where autonomic dysfunction, with profound brady-
cardia and blood pressure fluctuations, preceded
the expected neurologic deficit. Early identification
of these signs assured early diagnostic testing and opportune treatment options. Although not all test-
ing evaluations are performed as first line options, close monitoring, and a multidisciplinary approach in
patients with GBS with autonomic dysfunction variant
is necessary for appropriate management and dimin-
ishing morbimortality [14].

Abbreviations

WBC: White blood cells; CT: Computed tomography; EKG: Electrocardiogram;
CPK: Creatine phosphokinase; CPK-MB: Creatine phosphokinase isoenzyme
MB; GBS: Guillain-Barré syndrome; IVIG: Intravenous immunoglobulin.

Acknowledgements

Alvaro Arenas, MD Pediatric Electrophysiologist, Congenital Heart Disease
Institute. Pediatric Cardiology Fellowship Program, Universidad del Rosario.
Bogotá, DC. Colombia for contributing with a better EKG image and initial
evaluation of our patient.

Edwin Flores, MD. Pediatric neurologist and Jesús Rodríguez, MD, adult
neurologist from Fundación Cardioinfantil (Bogotá, DC, Colombia) for hospital
evaluation of our patient.

Authors’ contributions

CB carried out the design and conceptualization of the manuscript, assisted in
literature review, and drafted parts of the manuscript. MIA assisted in literature
review, cross-referencing, interpretation of data, and drafted substantial parts
of the manuscript. CU aided in drafting a substantial part the manuscript,
translated it into English and substantively revised it throughout the publica-
tion process. JF assisted in literature review, cross-referencing, and interpre-
tation of data, as well as drafting parts of the original manuscript. All four
authors (CB, MIA, CU, and JF) have read and approved the original manuscript,
as well as all subsequent modified versions.

Funding

The authors did not receive financial support for the investigation, authoring
and/or publication of this article. No funding was obtained for this study.

Availability of data and materials

Not applicable. All resources cited throughout the text are referenced in the
Bibliography section.

Declarations

Ethics approval and consent to participate
All protocols of the workplace on the publication of patient data were
followed, as well as obtained informed consent of patients and/or subjects
referred to in Article consent. This study had been reviewed and approved by
the Institutional Ethics Committee at Fundación Cardioinfantil IC University
Hospital, in accordance with the Declaration of Helsinki.

Consent for publication

The patient’s parent has given their Parental consent for this study.
Written consent to publish identifying images and/or other personal/clinical
details was obtained by both the patient and her parents prior to the submis-
sion of this manuscript.

Competing interests

The authors declare that there were no financial and/or non-financial compet-
ating interests for this case. There are no potential conflicts of interest with
respect to the investigation, author and/or publication of this article to declare.

Author details

1 Pediatric Cardiovascular Intensive Care Unit, Fundación Cardioinfantil IC
University Hospital. Pediatric Intensive Care Unit, Fundación Santa Fe de
Bogotá University Hospital, Bogotá, Colombia. 2 Section of Pediatric Infectious
Diseases, Fundación Cardioinfantil IC University Hospital. Pediatric Infectious
Diseases Fellowship Program, Universidad El Bosque, Bogotá, Colombia.
3 Medical doctor Universidad de los Andes. Pediatric resident Fundación Santa
Fe de Bogotá University Hospital, Bogotá, Colombia. 4 Pediatric Intensive Care
Unit, Fundación Cardioinfantil IC University Hospital. Pediatric Intensive Care
Fellowship Program, La Sabana University, Bogotá, Colombia.

Received: 9 April 2021 Accepted: 16 February 2022

Published online: 22 March 2022

References

1. Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautono-
mia in Guillain-Barré Syndrome: prevalence, clinical spectrum, and
outcomes. Neurocrit Care. 2020;32(7):173–20. https://doi.org/10.1007/
s10029-019-00781-w.

2. Zaeem Z, Siddiqi ZA. Zochodne DW Autonomic involvement in Guillain-
Barré syndrome: an update. Clin Auton Res. 2019;29(3):289–99. https://
doi.org/10.1007/s10286-018-0542-y.

3. Osler W. The principles and practice of medicine: designed for the use of
practitioners and students of medicine. New York: D. Appleton and Com-
pany; 1892. p. 777–8. https://ia802605.us.archive.org/12/items/principles
andpr00oslegoog/principlesandpr00oslegoog.pdf [Downloaded Sep 6, 2020]

4. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a
review. Muscle Nerve. 1994;17(10):1145–55. https://doi.org/10.1002/mus.
880171004.

5. Bredin CP. Guillain-Barré syndrome: the unsolved cardiovascular prob-
lems. J Med Sci. 1977;146(9):273–9. https://doi.org/10.1007/BF030
30974.

6. Flachenecker P, Müllges W, Wermuth P, Hartung HP, Reinis K. Eyeball
pressure testing in the evaluation of serious bradyarrhythmias in Guillain-
Barré syndrome. Neurology. 1996;47(1):102–8. https://doi.org/10.1212/
wnl.47.1.102.
7. Mukerji S, Aloka F, Farooq MU, Kassab MV, Abela GS. Cardiovascular complications of the Guillain-Barré syndrome. Am J Cardiol. 2009;104(10):1452–5. https://doi.org/10.1016/j.amjcard.2009.06.069.

8. Vassilieva A, Olsen MH, Perikhofer C, Knudsen GM, Kondziella D. Automated pupillometry to detect command following in neurological patients: a proof-of-concept study. Peer J 2019;7:e6929. https://doi.org/10.7717/peerj.6929.

9. Burns TM, Lawn ND, Low PA, Camilleri M, Wijdicks EF. Adynamic ileus in severe Guillain-Barré syndrome. Muscle Nerve. 2001;24(7):963–5. https://doi.org/10.1016/S0148-6191(01)00617-5.

10. Nachamkin I, Allos BM, Ho T. Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev. 1998;11(3):555–67.

11. Ventura HO, Messerli FH, Baron RE. Norepinephrine-induced hypertension in Guillain-Barré syndrome. J Hypertens. 1986;4(3):265–7. https://doi.org/10.1097/00004872-198606000-00002.

12. Ahmad J, Kham AS, Siddiqui MA. Estimation of plasma and urinary catecholamines in Guillain-Barré syndrome. Jpn J Med. 1985;24(1):24–9. https://doi.org/10.2169/internalmedicine1962.24.24.

13. van Doorn PA. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). Presse Med. 2013;42(6 Pt 2):e193–201. https://doi.org/10.1016/j.lpm.2013.02.328.

14. Abdel-Mannan O, D’Argenzio L, Pitt M, et al. Two cases of Guillain-Barré syndrome variants presenting with dysautonomia. Child Neurol Open. 2019;6:2329048X19856778. Published 2019 Jun 16. https://doi.org/10.1177/2329048X19856778.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.